RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 201 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.72 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $21,758,505 | +140.5% | 2,901,134 | +219.6% | 0.26% | +233.8% |
Q1 2024 | $9,048,932 | +1.1% | 907,616 | 0.0% | 0.08% | +1.3% |
Q4 2023 | $8,949,094 | +28.9% | 907,616 | 0.0% | 0.08% | +81.0% |
Q3 2023 | $6,943,262 | -70.8% | 907,616 | -71.4% | 0.04% | -68.4% |
Q2 2023 | $23,740,997 | -26.2% | 3,178,179 | -34.1% | 0.13% | -39.3% |
Q1 2023 | $32,187,653 | -13.5% | 4,825,735 | 0.0% | 0.22% | +25.9% |
Q4 2022 | $37,206,417 | -23.8% | 4,825,735 | +5.2% | 0.17% | -39.6% |
Q3 2022 | $48,809,000 | +30.7% | 4,587,274 | 0.0% | 0.29% | -50.1% |
Q2 2022 | $37,341,000 | +13.7% | 4,587,274 | 0.0% | 0.58% | +43.5% |
Q1 2022 | $32,845,000 | -51.1% | 4,587,274 | +16.9% | 0.40% | -40.9% |
Q4 2021 | $67,213,000 | -25.6% | 3,923,713 | 0.0% | 0.68% | +78.9% |
Q3 2021 | $90,285,000 | -35.9% | 3,923,713 | +1.7% | 0.38% | -51.4% |
Q2 2021 | $140,839,000 | – | 3,858,617 | – | 0.78% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
Artal Group S.A. | 960,204 | $7,403 | 0.41% |